Drug Profile


Alternative Names: KHK 4580; KHK-7580; MT-4580

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Kyowa Hakko Kirin
  • Class Antithyroids; Naphthalenes; Pyrrolidines; Small molecules
  • Mechanism of Action Calcium-sensing receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Secondary hyperparathyroidism
  • Phase III Primary hyperparathyroidism

Most Recent Events

  • 14 Aug 2017 Chemical structure information added
  • 01 Aug 2017 Phase-III clinical trials in Primary hyperparathyroidism in Japan (PO) (JapicCTI-173684)
  • 30 Apr 2017 Preregistration for Secondary hyperparathyroidism in Japan (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top